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Although the use of prophylactic granulocyte colony-stimulating factor (G-CSF) in conjunction with myelosuppressive chemotherapy
is supported by clinical research evidence and advocated by international clinical guidelines when the consequent risk of febrile
neutropenia exceeds 20%, there remains doubt as to the cost-effectiveness of the practice. There are limited economic data, and the
data that are available are not necessarily applicable to the management of breast cancer in a European setting. Much of the available
evidence on G-CSF in the management of febrile neutropenia is partial, focusing primarily on direct costs to the health service – that
is, those related to hospitalisation and drug treatment. A full assessment of the cost effectiveness of G-CSF prophylaxis needs to take
account of both costs and outcomes, including mortality, quality of life and patient functioning. As febrile neutropenia has been shown
to affect productivity, consideration should also be given to quantifying the indirect costs of neutropenia.
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Although the rate of breast cancer has increased in recent decades,
patient survival has improved largely as a result of effective
chemotherapy regimens (Peto et al, 2007), in particular the
widespread use of taxanes, such as docetaxel (Peto et al, 2007).
However, many of the chemotherapeutic regimens that improve
patient survival are associated with myelosuppression, which can
lead to the development of adverse events, notably neutropenia
(Kuderer et al, 2006). Neutropenia typically results in fever-like
symptoms (febrile neutropenia, FN) and increases patients’
susceptibility to the development of severe infections (Eldar-Lissai
et al, 2008), which can be life-threatening (Aapro et al, 2006).
Historically, neutropenia has been managed through chemother-
apy dose reductions, designed to reduce the level of myelosup-
pression. However, such dose reductions can also reduce the
clinical effectiveness of chemotherapy and may have a negative
impact on patient outcomes.
Use of granulocyte colony-stimulating factors (G-CSFs) is
increasingly being recognised as a means of managing FN without
resorting to chemotherapy dose reductions (Aapro et al, 2006).
Evidence for the efficacy of this practice is presented elsewhere in
this supplement (Kelly and Wheatley, 2009), and its use in the
primary prophylaxis of FN has been endorsed by best practice
guidelines. The American Society of Clinical Oncology (ASCO)
recommends primary prophylaxis with G-CSF for patients who are
at elevated risk of FN, as judged by a combination of factors,
including patient age, medical history, disease characteristics and
toxicity of the chemotherapy regimen (Smith et al, 2006). Although
ASCO earlier recommended the use of G-CSF when the risk of FN
was greater than 40% (Ozer et al, 2000), the latest guidelines use
the lower threshold of 20%, in acknowledgement of more recent
clinical evidence. Similar recommendations, also based on the 20%
threshold, have been issued by both the European Organization for
Research and Treatment of Cancer (EORTC) (Aapro et al, 2006)
and the National Comprehensive Cancer Network (NCCN)
(Crawford et al, 2009). EORTC also advocates selective use of G-
CSF where the risk of FN is estimated to be 10–20%. Guidance on
the use of secondary prophylaxis for patients who have previously
experienced a neutropenic event is included in the guidelines
(Smith et al, 2006; Crawford et al, 2009).
However, there are concerns about the financial implications
of the widespread use of G-CSF in early-stage breast cancers
(Ozer et al, 2000; Smith et al, 2006). ASCO’s decision to reduce the
FN-risk threshold for primary prophylaxis from 40 to 20%, as well
as the endorsements by EORTC and NCCN, has increased the
eligible population for G-CSF and the financial costs of using it in
accordance with the guidelines. Commentators have questioned
whether this extra cost is justified (Adams et al, 2006).
This paper attempts to summarise some of the economic
implications of the more widespread adoption of G-CSF and
considers whether the recommendations presented in the clinical
guidelines might be considered cost effective.
A discussion of the costs of using prophylactic antibiotics (as
discussed by Cullen and Baijal (2009) in this supplement), either in
combination with or in place of G-CSF, is not included. It is sufficient
to say that the direct costs associated with antibiotics are largely
negligible in the context of the costs of treating breast cancer.
THE COSTS OF FN: DIRECT AND INDIRECT
FN is recognised as a costly side effect of chemotherapy for breast
cancer. It is associated with direct costs (those incurred by the
health-care payer) and indirect costs (those incurred by the patient
and caregivers). Table 1 provides a breakdown of some of the
costs that should be considered when trying to determine the
cost-effectiveness of a preventative approach to FN management. *Correspondence: P Trueman; E-mail: pt507@york.ac.uk
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needs to be given to the intangible costs incurred by patients.
Estimates of the direct costs of managing FN vary substantially.
They depend on various factors, including the care setting, the
particular cancer and the severity of the episode. Studies from the
United States tend to report higher costs than do those from Europe.
Bennett and Calhoun (2007) have reviewed both the direct and
indirect costs of FN in North America, based on the type of cancer
being treated, and on whether FN was managed principally on an
outpatient or inpatient basis, in 71 patients recruited from 10
community oncology centres. Among those with breast cancer, FN
was associated with a direct cost of $1094 (Bd730) per episode
treated in outpatient settings, and $10354 (Bd6950) per episode
treated in inpatient settings. For those treated as inpatients,
FN-related hospitalisations accounted for over 75% of the costs,
whereas medications accounted for the majority of the costs in
outpatients. Indirect costs for patients with breast cancer who
developed FN were estimated to be $1530 (Bd1030) for out-
patients and $2832 (Bd1900) for inpatients, and were attributed to
work loss and caregiver time.
In a retrospective study from Spain, the estimated cost of FN
was h3519 (Bd2360) per episode (Mayordomo et al, 2006). This is
broadly in line with estimates from the United Kingdom, where the
reference cost (essentially the charge to the payer) for an
admission with FN is approximately d3300–d4300 and a recent
review conducted by the National Institute for Health and Clinical
Excellence (NICE) estimated a cost of about d3330 per FN episode
(NICE, 2008).
COST OF PROPHYLACTIC G-CSF
US perspective
Analysis of more than 24000 patients hospitalised with FN in the
United States, conducted as part of an economic evaluation of
G-CSF (Eldar-Lissai et al, 2008), indicated that the mean length of
stay was 9 days for patients who survived FN and 15 days for those
who died as a result of it. The mean cost of FN management per
day ranged from $1984 (Bd1330) to $3139 (Bd2100). On the basis
of research published earlier, the authors assumed that the use of
prophylactic G-CSF would reduce the length of hospital stay by
20%, thus saving several thousand dollars per patient.
The authors acknowledge that their study has a number of
limitations, including the use of evidence drawn from a number of
different trials, and the application of data to a hypothetical patient
population. From a European perspective, the most notable
limitation is the higher cost of inpatient FN management in the
United States compared with Europe. Evidence from European
studies of prophylactic G-CSF (used in combination with antibiotics)
suggests that the economic case may be less convincing in European
settings, because of the lower cost of managing FN episodes.
However, as stated earlier, the cost of managing FN has been found
to differ across malignancies, and therefore the relevance of this
evidence to breast cancer is uncertain.
UK perspective
In the United Kingdom, the cost of G-CSF prophylaxis during
breast cancer chemotherapy has been estimated at d3100–d5900
per patient, for six cycles (All Wales Medicines Strategy Group,
2008).
Thus, on the basis of direct costs alone, prophylaxis may not
compare favourably with the cost of managing an episode of FN as
discussed above (e.g., d3330, according to the NICE analysis).
However, this crude financial calculation takes no account of the
indirect costs of FN, as well as the benefits of prophylactic
treatment in terms of avoiding neutropenic episodes and the
resultant impact on the individual patient’s mortality and quality
of life. A full economic evaluation of prophylactic G-CSF should
capture both the direct costs (acquisition costs, treatment costs
and impact on other health-care resources) and consider the
indirect costs (e.g., lost productivity, patient travel time and
impact on patient outcomes). A broad perspective that takes
account of the full range of costs associated with FN would likely
lead to a more favourable conclusion for primary prophylaxis.
CONCLUSION
Best practice guidelines from both North America and Europe
recommend selective use of G-CSF for primary prophylaxis of FN.
There is consensus across the guidelines, which recommend G-CSF
for individuals whose risk of FN exceeds 20%.
There is only limited economic evidence for the cost effective-
ness of implementing this recommendation, and a great deal of
variation between findings from studies in the USA and Europe
because of differences in the estimated cost of managing an
episode of FN. Further research evidence is needed to allow
accurate estimation of the costs of managing FN specifically in
patients with breast cancer, in Europe, which seeks to capture the
direct, indirect and intangible costs associated with FN. Such
research will help to determine the most economically advanta-
geous positioning of G-CSF in the management of breast cancer, so
that patients receive the best possible care while scarce health-care
resources are allocated appropriately.
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